Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
Keyword(s):
Keyword(s):
Keyword(s):
2007 ◽
Vol 5
(4)
◽
pp. 362
◽
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8056-8056
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8046-8046
◽
Keyword(s):
2019 ◽
Vol 25
(7)
◽
pp. 2088-2095
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. LBA7512-LBA7512
◽
Keyword(s):